RE:RE:RE:RE:Partners
noin, as best i know the structure is pretty dogmatic and as MCNA is oncology and urology it gets both..now i suspect if i remember correctly at least one oncy doc was brain cancer and i betcha if MCNA hadda been brain cancer she woulda voted yes...but i betcha the FDA understands the value of non-practicing advice better than us (ie likely about zero and more opinion than advice)..ps as a comparable around the same time T-VEC (amgen for multi-myl) did Adcom and had no demonstrated benefit (statistically proven no doubt about it) and no safety issues, but all docs were in that world and it got Adcom thums up and FDA approval.. by various types of these benchmarks i am confident MCNA will be approved (although must say T-VEC as it was bleeding edge virus therapy had a ton of trials and support data)...but who knows for sure, likely at this time not even the FDA...i will add this as no extension NRed i say the FDA is going either yes or no, so whatever Adcom impact was it has been absorded into the process with no tmeline hiccups (ie FDA didnt ask TST to redo data to tease out surgery unwilling or unable)